Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Allogeneic bone marrow transplantation (BMT) in a patient with myelodysplastic syndrome (MDS) infected by hepatitis B virus (HBV) precore mutant: favorable outcome with slow tapering of immunosuppressive agents

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Locasciulli A, Testa M, Velsecchi MG, Vecchi L, Longoni D, Sparano P, Rovelli A, Uderzo C, Masera G, Alberti A . Morbidity and mortality due to liver disease in children undergoing allogeneic bone marrow transplantation: a 10-year prospective study Blood 1997 90: 3799–3805

    CAS  PubMed  Google Scholar 

  2. Pariente EA, Goudeau A, Dubois F, Degott C, Gluckman E, Devergie A, Berchot C, Schenmetzler C, Bernuau J . Fulminant hepatitis due to reactivation of chronic hepatitis B virus infection after allogeneic bone marrow transplantation Dig Dis Sci 1988 33: 1185–1191

    Article  CAS  Google Scholar 

  3. McIvor C, Morton J, Bryant A, Cooksley WG, Durrant S, Walker N . Fatal reactivation of precore mutant hepatitis B virus associated with fibrosing cholestatic hepatitis after bone marrow transplantation Ann Int Med 1994 121: 274–275

    Article  CAS  Google Scholar 

  4. Miura Y, Takamatsu H, Okumura H, Yoshida T, Nakao S, Matsuda T . Allogeneic bone marrow transplantation for a patient complicated by chronic hepatitis due to precore mutant hepatitis B virus: failure of management with interferon-α therapy Am J Hematol 1997 54: 344–345

    Article  CAS  Google Scholar 

  5. Kikuchi A, Ohashi H, Hanada R, Yamamoto K . Low-dose cytarabine (AraC) + recombinant human granulocyte colony-stimulating factor (rhG-CSF) for myelodysplastic syndrome (MDS) Leukemia 1999 13: 980–981

    Article  CAS  Google Scholar 

  6. Reed EC, Myerson D, Corey L, Myers JD . Allogeneic bone marrow transplantation in patients positive for hepatitis B surface antigen Blood 1990 77: 195–200

    Google Scholar 

  7. Lau GKK, Liang R, Chiu EK, Lee CK, Lam SK . Hepatic events after bone marrow transplantation in patients with hepatitis B infection: a case controlled study Bone Marrow Transplant 1997 19: 795–799

    Article  CAS  Google Scholar 

  8. Junker-Niepmann M, Bartenschalager R, Shaller H . A short cis-acting sequence is required for hepatitis B virus pregenome encapsidation and sufficient for packaging of foreign RNA EMBO 1990 9: 3389–3396

    Article  CAS  Google Scholar 

  9. Lau GK, Lok AS, Liang RH, Lai CL, Chiu EK, Lau YL, Lam SK . Clearance of hepatitis B surface antigen after bone marrow transplantation: role of adoptive immunity transfer Hepatology 1997 25: 1497–1501

    Article  CAS  Google Scholar 

  10. Ito S, Nakazono K, Murasawa A, Mita Y, Hata K, Saito N, Kikuchi M, Yoshida K, Nakano M, Gejyo F . Development of fluminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient Arthritis Rheum 2001 44: 339–342

    Article  CAS  Google Scholar 

  11. Dai MS, Lu JJ, Chen YC, Perng CL, Chao TY . Reactivation of precore mutant hepatitis B virus in chemotherapy-treated patients Cancer 2001 92: 2927–2932

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kikuchi, A., Kagimoto, S., Kishimoto, H. et al. Allogeneic bone marrow transplantation (BMT) in a patient with myelodysplastic syndrome (MDS) infected by hepatitis B virus (HBV) precore mutant: favorable outcome with slow tapering of immunosuppressive agents. Leukemia 16, 2333–2335 (2002). https://doi.org/10.1038/sj.leu.2402649

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2402649

Search

Quick links